Aardvark Therapeutics Inc (AARD)

$14.26 +0.11 (0.78%)
Market Cap 308.09M
Revenue (ttm) 0.00
Net Income (ttm) -20.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 63,700
Avg Vol 211,356
Day's Range N/A - N/A
Shares Out 21.77M
Stochastic %K 44%
Beta N/A
Analysts Strong Sell
Price Target $32.70

Company Profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 225 7696
Address:
4370 La Jolla Village Drive, Suite 1050, San Diego, United States
MergerMaster
MergerMaster Dec. 24 at 10:36 AM
$AARD Expectations are now anchored to how progress validates the underlying thesis beyond narrative appeal. Execution slippage remains the dominant downside risk.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 1:59 PM
$AARD RSI: 75.41, MACD: 0.8772 Vol: 2.13, MA20: 12.52, MA50: 11.72 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
notreload_ai
notreload_ai Dec. 23 at 12:45 PM
Oppenheimer analyst gives $AARD an Outperform rating with $35 price target, highlighting rare and common obesity drug programs and a key Phase 3 trial. https://notreload.xyz/oppenheimer-starts-coverage-on-aardvark-therapeutics-with-strong-rating/
0 · Reply
Quantumup
Quantumup Dec. 23 at 12:17 PM
Oppenheimer🏁 $AARD Outperform-$35 and said: We initiate coverage with an Outperform rating and a $35 PT as AARD builds a differentiated rare and common obesity franchise-and ahead of next year's key readout. $SLNO $RYTM Oppenheimer added: Lead program is a global Phase 3 trial for Prader-Willi syndrome, a $1B+ US TAM for which favorable safety alone could make ARD-101 competitive to the sole currently approved option. Topline data due 3Q26. AARD is also pursuing several avenues to advance the treatment condition for general obesity, for which injectable GLP-1 drugs—despite their impressive sales growth—are far from perfect and have created opportunities for innovative oral therapeutics that could be used in complement with them or as independent alternatives. Cash runway sufficient to reach key catalysts that we expect to drive share outperformance from current <$200M EV.
0 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 11:40 AM
Oppenheimer has adjusted their stance on Aardvark Therapeutics ( $AARD ), setting the rating to Outperform with a target price of 35.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 19 at 12:08 AM
$AARD
0 · Reply
Quantumup
Quantumup Dec. 17 at 4:24 PM
Guggenheim⬆️ $RYTM's PT to $140/reit'd at Buy $SLNO $AARD Canaccord Genuity 12/12⬆️PT to $141 from $114, plus added $2.1 B peak sale@ 50% PoS in PWS to its model; reit'd Buy Citizens 12/12⬆️PT to $167 from $141—reit'd Mkt OP/now includes PWS@ 50% POS/peak🇺🇸sales=$700M in '32 Here's what the Analysts had to say:
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 4:28 PM
William Blair has adjusted their stance on Aardvark Therapeutics ( $AARD ), setting the rating to Outperform.
0 · Reply
Quantumup
Quantumup Dec. 11 at 6:30 PM
BofA⬆️ $RYTM's PT to $140 from $127, reiterated at a Buy rating and said, 'Encouraging Early BMI and Hyperphagia Reduction Signal—Model Changes' $SLNO $AARD Morgan Stanley⬆️PT to $150 from $129, reit'd at Buy/said, Preliminary Ph2 setmelanotide data in PWS indicate promising and consistent signs of activity (BMI and hyperphagia) despite a challenging population supporting advancement into Ph3. We view early data as encouraging, indicating potential to expansion into another blockbuster opportunity. Here's what else BofA had to say: https://x.com/Quantumup1/status/1999184429684822485?s=20
0 · Reply
Quantumup
Quantumup Dec. 11 at 5:31 PM
Raymond James reiterated $AARD Strong Buy/$47 $RYTM $SLNO Raymond James said—Remain Strong Buy rated on AARD shares following Rhythm's (RYTM, not covered) presentation of preliminary Phase 2 data for setmelanotide in PWS. Recall, this drug's mechanism differs from ARD-101 and it appears the drug's clinical utility differs as well. As we highlight herein, setmelanotide appears to impact BMI more that hyperphagia, and given the complexity of this disease, we think combination therapy is likely where standard of care is headed. Given this, we think ARD-101's value proposition as potentially best-in-class in controlling hyperphagia remains intact.
0 · Reply
Latest News on AARD
Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst

Dec 12, 2025, 2:04 PM EST - 13 days ago

Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

Dec 10, 2025, 4:05 PM EST - 15 days ago

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

Nov 25, 2025, 4:05 PM EST - 4 weeks ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Nov 13, 2025, 4:05 PM EST - 6 weeks ago

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Nov 11, 2025, 4:05 PM EST - 6 weeks ago

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

Nov 4, 2025, 12:00 PM EST - 7 weeks ago

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Nov 3, 2025, 5:55 PM EST - 7 weeks ago

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

Nov 3, 2025, 8:00 AM EST - 7 weeks ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

Oct 22, 2025, 8:00 AM EDT - 2 months ago

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

Oct 8, 2025, 8:00 AM EDT - 2 months ago

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 23, 2025, 4:05 PM EDT - 3 months ago

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Aardvark Therapeutics, Inc. (AARD) Presents At Cantor Fitzgerald Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 1:25 AM EDT - 4 months ago

Aardvark Therapeutics, Inc. (AARD) Presents At Cantor Fitzgerald Global Healthcare Conference 2025 Transcript

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

Aug 27, 2025, 4:10 PM EDT - 4 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aug 13, 2025, 4:10 PM EDT - 4 months ago

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

Aug 12, 2025, 8:00 AM EDT - 4 months ago

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Jul 18, 2025, 8:00 AM EDT - 5 months ago

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

Jun 24, 2025, 8:00 AM EDT - 6 months ago

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

May 19, 2025, 4:10 PM EDT - 7 months ago

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 14, 2025, 4:10 PM EDT - 8 months ago

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

May 7, 2025, 4:05 PM EDT - 8 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Mar 31, 2025, 4:10 PM EDT - 9 months ago

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

U.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO Week

Feb 14, 2025, 11:50 PM EST - 11 months ago

U.S. IPO Weekly Recap: Big Listings Post Mixed Results In Busy 7 IPO Week

AGH KMTS KRMN NPB ODYS SAIL XHLD

Aardvark Therapeutics Announces Pricing of Initial Public Offering

Feb 12, 2025, 10:38 PM EST - 11 months ago

Aardvark Therapeutics Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

Feb 8, 2025, 2:30 AM EST - 11 months ago

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

AGH FBGL HCAI KRMN NPB ODYS PLUT

Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments

Feb 3, 2025, 11:52 AM EST - 11 months ago

Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments

MergerMaster
MergerMaster Dec. 24 at 10:36 AM
$AARD Expectations are now anchored to how progress validates the underlying thesis beyond narrative appeal. Execution slippage remains the dominant downside risk.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 1:59 PM
$AARD RSI: 75.41, MACD: 0.8772 Vol: 2.13, MA20: 12.52, MA50: 11.72 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
notreload_ai
notreload_ai Dec. 23 at 12:45 PM
Oppenheimer analyst gives $AARD an Outperform rating with $35 price target, highlighting rare and common obesity drug programs and a key Phase 3 trial. https://notreload.xyz/oppenheimer-starts-coverage-on-aardvark-therapeutics-with-strong-rating/
0 · Reply
Quantumup
Quantumup Dec. 23 at 12:17 PM
Oppenheimer🏁 $AARD Outperform-$35 and said: We initiate coverage with an Outperform rating and a $35 PT as AARD builds a differentiated rare and common obesity franchise-and ahead of next year's key readout. $SLNO $RYTM Oppenheimer added: Lead program is a global Phase 3 trial for Prader-Willi syndrome, a $1B+ US TAM for which favorable safety alone could make ARD-101 competitive to the sole currently approved option. Topline data due 3Q26. AARD is also pursuing several avenues to advance the treatment condition for general obesity, for which injectable GLP-1 drugs—despite their impressive sales growth—are far from perfect and have created opportunities for innovative oral therapeutics that could be used in complement with them or as independent alternatives. Cash runway sufficient to reach key catalysts that we expect to drive share outperformance from current <$200M EV.
0 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 11:40 AM
Oppenheimer has adjusted their stance on Aardvark Therapeutics ( $AARD ), setting the rating to Outperform with a target price of 35.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 19 at 12:08 AM
$AARD
0 · Reply
Quantumup
Quantumup Dec. 17 at 4:24 PM
Guggenheim⬆️ $RYTM's PT to $140/reit'd at Buy $SLNO $AARD Canaccord Genuity 12/12⬆️PT to $141 from $114, plus added $2.1 B peak sale@ 50% PoS in PWS to its model; reit'd Buy Citizens 12/12⬆️PT to $167 from $141—reit'd Mkt OP/now includes PWS@ 50% POS/peak🇺🇸sales=$700M in '32 Here's what the Analysts had to say:
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 4:28 PM
William Blair has adjusted their stance on Aardvark Therapeutics ( $AARD ), setting the rating to Outperform.
0 · Reply
Quantumup
Quantumup Dec. 11 at 6:30 PM
BofA⬆️ $RYTM's PT to $140 from $127, reiterated at a Buy rating and said, 'Encouraging Early BMI and Hyperphagia Reduction Signal—Model Changes' $SLNO $AARD Morgan Stanley⬆️PT to $150 from $129, reit'd at Buy/said, Preliminary Ph2 setmelanotide data in PWS indicate promising and consistent signs of activity (BMI and hyperphagia) despite a challenging population supporting advancement into Ph3. We view early data as encouraging, indicating potential to expansion into another blockbuster opportunity. Here's what else BofA had to say: https://x.com/Quantumup1/status/1999184429684822485?s=20
0 · Reply
Quantumup
Quantumup Dec. 11 at 5:31 PM
Raymond James reiterated $AARD Strong Buy/$47 $RYTM $SLNO Raymond James said—Remain Strong Buy rated on AARD shares following Rhythm's (RYTM, not covered) presentation of preliminary Phase 2 data for setmelanotide in PWS. Recall, this drug's mechanism differs from ARD-101 and it appears the drug's clinical utility differs as well. As we highlight herein, setmelanotide appears to impact BMI more that hyperphagia, and given the complexity of this disease, we think combination therapy is likely where standard of care is headed. Given this, we think ARD-101's value proposition as potentially best-in-class in controlling hyperphagia remains intact.
0 · Reply
justiceforb_85
justiceforb_85 Dec. 7 at 2:47 AM
$AARD finally coming to life.
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 8:00 PM
Top Gainers PT2 $QCLS $KXIN $MPLT $AARD $PMAX
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 5:56 PM
Top Gainers PT2 $KXIN $QCLS $AHMA $AARD $SMX
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 2:55 PM
Top Gainers PT2 $PMAX $KXIN $CGCTW $AARD $WSHP
0 · Reply
topstockalerts
topstockalerts Dec. 2 at 10:43 PM
After Hours Top Gainers PT2 $MRVL $AARD $IPW $ZOOZ $BLNE
0 · Reply
notreload_ai
notreload_ai Dec. 2 at 9:41 PM
Raymond James initiates $AARD with a Strong Buy and a $47 price target, highlighting strong Phase 2 data for ARD-101 and unmet needs in hyperphagia treatment. https://notreload.xyz/aardvark-therapeutics-rated-strong-buy-by-raymond-james/
0 · Reply
Quantumup
Quantumup Dec. 2 at 9:29 PM
Raymond James🏁 $AARD Strong Buy/$47 $SLNO $RYTM $LLY $NVO VKTX Here's what Raymond James said in its initiation report: https://x.com/Quantumup1/status/1995967645267771758?s=20
1 · Reply
Quantumup
Quantumup Nov. 17 at 9:31 PM
Wolfe Research🏁 $SLNO Outperform-$75, and said, Hungry for More Sales. Initiate at OP $RYTM $AARD Wolfe Research added We are initiating coverage of Soleno Therapeutics (SLNO) with an Outperform rating, $75 PT. With the recent FDA approval of Vykat XR — the only approved therapy for hyperphagia in PWS — we believe the stock is entering a new phase of value creation. Despite high volatility in SLNO shares, partly driven by a short report (Aug 15, 2025; by Scorpion Capital; link) we view as overstated, we see the recent weakness as a buying opportunity. Our conviction is based on SLNO's first-mover advantage and the directional trend of our prescriber survey data (n=15).
0 · Reply
laaarsas
laaarsas Nov. 16 at 5:04 AM
$AARD what is vibe here?
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 3:36 PM
RBC Capital has adjusted their stance on Aardvark Therapeutics ( $AARD ), setting the rating to Market Outperform with a target price of 19 → 18.
0 · Reply
Quantumup
Quantumup Nov. 14 at 1:37 PM
Stifel reiterated $AARD Buy-$24 $SLNO $RYTM Stifel said: Most important to the stock, ARD-101's registrational ph3 HERO RCT in PWS remains on track with topline data anticipated in 3Q26. As outlined in our recent initiation (LINK), we continue to think there's an interesting risk/ reward into data with: (1) a ph2 clinical signal (looks similar to Vykat/beyond typical placebo); (2) an interesting biological/mechanistic story; and (3) a smart ph3 trial design that should help optimize the POS. Elsewhere, Aardvark continues to progress ARD-201 in obesity -- last week they presented interesting/supportive preclinical data across multiple relevant/predictive animal models (LINK). Initial ph2 POWER weight-maintenance data are expected 2H26 where, with no credit today (and significant investor/strategic interest in the space), we think there's interesting optionality for the stock. We also just hosted Aardvark at our healthcare conference, where we discussed ARD-101 and ARD-201 in much more detail.
0 · Reply
d_risk
d_risk Nov. 13 at 9:58 PM
$AARD - Aardvark Therapeutics, Inc. - 10Q - Updated Risk Factors AARD’s 10-Q risk factors now focus on limited operating history, ongoing losses, heavy reliance on ARD-101, major financing needs, regulatory and clinical trial hurdles, post-marketing risks, expanded IP litigation threats, commercialization and reimbursement challenges, new social media and short-seller risks, and heightened compliance and volatility concerns, with many prior risk headings removed or streamlined. #Biotechnology #IntellectualProperty #FinancingNeeds #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/AARD/10-Q/2025-11-13
0 · Reply